For instance, the potency of the SMO inhibitor glasdegib (PF-04449913) alone or in combination with e.g. 5-Aza or chemotherapy is being investigated in several clinical trials for hematologic malignancies including MDS and AML (http://clinicaltrials.org, NCT01842646, NCT01841333, NCT01546038, NCT02367456). The gene discussed is SMO; the disease is acute myeloid leukemia.